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1. Introduction  
Alzheimer´s disease (AD) is a condition mainly diagnosed through clinical interpretation 
and neuropsychological testing. Unfortunately this leads to problems due to variations in 
expertise of the clinicians involved. Moreover, its diagnosis is usually achieved in later 
phases of the disease, which reduces the scope of useful interventions. In this chapter we 
will review the different brain imaging approaches used for both AD and mild cognitive 
impairment (MCI), a condition which evolves into AD in an important proportion of cases 
(between 10-15 % yearly) (Petersen, 2008).  
It has been hypothesized that the accumulation of β-amyloid (Aβ) in the AD brain triggers a 
cascade of neurodegenerative events, including inflammatory processes, neurofibrillary 
tangles, oxidative stress, and neuronal network dysfunction with synaptic loss and 
neurotransmitter deficits. Such events are manifested by progressive impairment of 
cognitive functions (Kadir et al, 2011). Years ago, an accurate diagnosis of AD was 
considered only possible using a demonstration of Aβ plaques and neurofibrillary tangles at 
post-mortem histopathological analysis of the brain (Wiley et al, 2009).  
At present there are promising methods for the in vivo assessment of the extent of AD. The 
typical findings of these brain imaging techniques are different and they are summarized in 
Table 1. These neuroimaging methods may help in AD early diagnosis as well as helping in 
differentiating AD from other neurodegenerative conditions. Although some pioneering 
work started in the 1970s, the explosion of knowledge regarding brain imaging methods for 
AD diagnosis is a matter of the last two decades.  
1.1 Computerized Tomography (CT)  
Nowadays CT is not considered a standard technique for diagnosing AD, least of all in early 
stages. Its main usefulness is in differential diagnosis since it is less expensive, faster and 
more widely available than MRI. CT allows ruling out some clinical situations which lead to 
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behavioural alterations but are not AD, e.g., normotensive hydrocephalus, intra and extra-
axial bleeding, etc.  
 
Neuroimaging 
technique 
Finding 
CT Tissue atrophy. 
MRI Tissue atrophy. It is more specific about grey matter. 
fMRI 
Changes in blood oxygenation level (BOLD signal) representing 
synaptic activity. 
DTI Connectivity and organization in white matter tracts. 
Spectroscopy Chemical content of the brain, such as NAA/Cr ratio or others. 
SPECT Changes in cerebral perfusion. 
PET Changes in glucose metabolism. 
PET-amyloid Measures accumulation of -amyloid, an AD-specific protein. 
MEG 
Measures magnetic fields and, indirectly, yields rather precise 
information about brain electrical activity 
CT = computerized tomography; MRI = magnetic resonance imaging; fMRI = functional magnetic 
resonance imaging; DTI = diffusion tensor imaging; SPECT = single-photon emission computed 
tomography; PET = positron emission tomography; MEG = magnetoencephalography; BOLD = blood 
oxygen level-dependent; NAA = N-acetyl aspartate; Cr = Creatinine; AD = Alzheimer’s disease  
Table 1. Typical findings of different brain imaging methods used in AD and MCI diagnosis  
1.2 Magnetic Resonance Imaging (MRI)  
1.2.1 Structural MRI 
This technique provides the best possible spatial resolution. Given the fact the most robust 
neuroimaging finding in AD is the atrophy of mesial temporal structures, structural MRI is the 
most widely used approach. Hippocampal atrophy is another well known finding, but 
atrophy within other brain areas has also been described in entorrhinal cortex, amygdala, basal 
ganglia (nucleus basalis of Meynert), thalamus and bilateral parietal cortex. It is relevant to 
mention here that in terms of early diagnosis some consider the entorrhinal cortex as the 
earliest area affected by AD. Other researchers have stated that the nucleus basalis of Meynert 
is a key structure in AD early diagnosis (Herholz et al, 2004; Grothe et al, 2010).  
1.2.2 Functional MRI (fMRI)  
fMRI provides signal intensities images associated with a relative cerebral blood flow 
during cognitive tasks. Resting and activation functional MRI studies have showed a lesser 
coordinated activity in the hippocampus, inferior parietal lobes –both bilaterally- and 
cingulate cortex in patients with AD. This neuroimaging technique is nowadays used to 
monitor AD patients’ treatment.  
Combining genetic risk with functional MRI memory task paradigms has shown to be a 
very accurate pre-symptomatic predictor of cognitive decline. 
1.3 Diffusion Tensor Imaging (DTI)  
DTI allows visualizing neuronal connectivity or, more precisely, local fiber orientation and 
white matter tracts integrity. Patients with AD show decreased fiber density in temporal 
white matter, probably related to the medial temporal grey matter atrophy, as well as in the 
splenium of the corpus callosum.  
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In mild cognitive impairment (MCI), however, this decreased fiber density has been located 
in the anterior part of the corpus callosum.  
1.4 Spectroscopy  
It provides information on tissue substrate or metabolite concentrations. Specifically the N-
acetyl aspartate (NAA) has been used as a biomarker of neuronal death, and it has been 
demonstrated that in patients with MCI and AD is significantly reduced compared to 
healthy controls. 
1.5 Nuclear medicine brain imaging techniques  
1.5.1 Single-photon emission computed tomography (SPECT)  
It measures cerebral flow by detecting a single-photon emitting tracer after its intravenous 
injection and brain uptake. It has a very low spatial resolution and its diagnostic accuracy is 
lower than PET. Nevertheless, in clinical practice, it can be useful for differentiating AD 
from other dementias such as frontotemporal dementia. 
1.5.2 Positron emission tomography (PET)  
Recently a new technique using PET with Pittsburg compound B (PIB; PIB-PET) has 
emerged. PIB is a tracer which allows marking β-amyloid plaques. This technique has been 
highly efficacious to detect β-amyloid in vivo and, therefore, could be rather useful to detect 
AD in its early phases.  
1.6 Magnetoencephalography (MEG)  
MEG is a technique which measures brain magnetic fields both during basal state and 
during cognitive activation. Its time resolution is measured in milliseconds. It is precisely 
this very high temporal resolution which allows evaluating small changes in brain 
processing during cognitive stimulation. These changes may help to differentiate between 
AD, MCI and normality as well as providing some clues about differences in information 
processing in these same conditions  
Different studies carried out with MEG show a decrease in magnetic fields in people with 
AD in temporal mesial areas during memory tasks. People suffering from AD exhibit 
increased slow frequencies in temporoparietal areas in basal evaluation.  
2. Computed Tomography (CT)  
Since the 1970s, there have been many CT studies searching for evidence of focal atrophy in 
the brains of subjects with AD (DeCarli et al, 1990). The search was complicated by the 
overlap between changes common to AD and normal ageing and because AD cases were 
only diagnosed clinically (Smith and Jobst, 1996). There are both generalized and focal 
changes, both in cortical areas as in the ventricular system, in brain atrophy. Unfortunately 
focal atrophy is not consistently found in standard axial CT studies though subjects with AD 
may show a greater degree of generalized atrophy revealed by sulci enlargement and 
ventricular dilatation.  
DeCarli et al (1990) concluded as follows: “Unfortunately, at present there is little definite 
evidence for clear anatomic brain changes that accurately predict the cognitive dysfunction 
within a group of patients suffering Alzheimer’s disease”. The dictum still remains valid.  
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The standard axial CT system used internationally does not show the medial temporal lobe 
well, mainly because of the scan angle used. Changes in the medial temporal lobe itself have 
to be inferred from dilatation of the temporal horns of the lateral ventricles and enlargement 
of the suprasellar cisterns. Indeed, these changes have been observed in AD (Kido et al, 
1989). By 1988, an alternative camera angle was used for hippocampus evaluation in 
patients with temporal lobe epilepsy and this system was also used by de Leon et al (1989) 
to study AD patients. The angle is parallel to the long axis of the temporal lobe and scanning 
is carried out from below and upwards until the inferior margin of the orbit is reached; in 
this way a complete series of images through the temporal lobe is obtained without 
exposing the eyes. Using this “temporal-lobe-oriented” CT procedure, de Leon et al (1989) 
found that 87% of patients with moderate to severe AD had dilatation of the hippocampal 
fissure compared with age-matched controls.  
Hippocampal atrophy detected with CT was also more common in a group that did not 
reach the clinical research criteria for AD but showed minimal memory impairments. This 
led them to suggest that hippocampal atrophy might be an AD marker which occurs early in 
the course of the illness, before the diagnosis is established, and predicts deterioration (De 
Leon et al, 1989). Hippocampal atrophy is not the only neuroimaging sign in AD, but it is 
rather characteristic.  
The axial temporal lobe oriented CT scan can be used to look for other possible causes of 
dementia, such as multiple infarcts, tumours or hydrocephalus, and the temporal lobe-
oriented scan (in 1.5-2 mm slices) to reveal atrophy of the medial temporal lobe (Smith et al, 
1996) (Fig 1).  
 
       
Fig. 1.  CT in AD on the left and a patient with normotensive hydrocephalus on the right, 
where a catheter can be seen. CT is helpful to differentiate between AD and other brain 
conditions.  
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Unfortunately CT usefulness in AD diagnosis is very limited (DeCarli et al, 1990). In the last 
20 years MRI became increasingly available and the vast majority of structural 
neuroimaging used since then has been MRI. This is the reason why there are no relevant 
papers written since then where CT has been used for AD. 
Atrophy is evident, at hippocampal level too. Dilatation of the lateral ventricles can also be 
seen.  
3. Structural magnetic resonance imaging (MRI)  
MRI volumetry was one of the earliest brain imaging techniques used to identify AD. Given 
the temporal lobe atrophy found in AD patients, it seemed that this finding per se could 
diagnose AD. Further research revealed this simplistic approach was flawed.  
The first technique was manual volumetry. This required an excellent working knowledge 
of neuroanatomy as well as good dexterity in delineating the ROIs (regions of interest). This 
method is highly operator-dependent and multiple subjective issues can arise. This is 
overcome by double or triple-blind studies. Manual volumetry is also very time-consuming. 
On the other hand you have to have a prior hypothesis, such as a ROI to analyze. There have 
been many hypotheses in AD. Hippocampal analysis stands out (Besga et al, 2010) amongst 
them, though more recently other structures, such as the caudate nucleus or thalamus (Skup 
et al, 2011), or even corpus callosum, are being considered.   
A newer method is the so-called Voxed-based morphometry (VBM). This is an 
authomatized approach which allows distinguishing between grey and white matter. It also 
allows performing statistical studies amongst different populations (Kinkingnéhun et al, 
2008).  
Multiple computer techniques have evolved since then. They allow analysing the brain, 
either globally or in any 3D ROI. For instance, in hippocampus, a key structure in AD, there 
are “radial atrophy mapping approach” or “large-deformation high dimensional brain 
mapping”. The former computes the 3D distance from the hippocampal centroid in each 
coronal section (also called a medial curve or core) to each hippocampal surface point. This 
provides an intuitive 3D measure of hippocampal thickness, as well as metric estimates of 
hippocampal atrophy that can be compared point-by-point across individuals and groups 
(Thompson et al, 2004). The latter is also used to study the changes in hippocampal 
morphology in patients with AD (Apostolova et al, 2007). Rather than relying on 
hippocampal manual tracings, a template hippocampus is traced on a single subject and 
fluidly warped to match the anatomy of new subjects. The transformation involved is high- 
dimensional, i.e. involves millions of degrees of freedom to produce a deformation that 
captures shape differences in detail. It is de facto a ‘large-deformation’ approach, that is to 
say the deformation model follows a continuum-mechanical law that prevents folding or 
tearing of the deforming template (this is known mathematically as a diffeomorphism). 
Similarly to VBM, many cortical computational anatomy techniques use the segmented grey 
matter maps and the grey matter density approach (Thompson et al, 2004) or a more 
advanced grey matter thickness approach (Lerch et al, 2005; Singh et al, 2006; Apostolova et 
al, 2008).  
Using the hippocampal radial atrophy mapping approach, Thompson et al (2004) showed 
profound hippocampal differences between normal controls and AD patients. These 
differences were correlated with MMSE scores. Two cross-sectional large-deformation high-
dimensional brain mapping hippocampal studies have suggested the CA1 subfield may 
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discriminate between normal aging and questionable AD (Clinical Dementia Rating Scale 
(CDR) = 0.5) (Csernansky et al, 2000; Wang et al, 2006).  
Along the last 10 years all sorts of volumetry studies aiming at early diagnosis of AD have 
been carried out. They mainly focus on either comparing AD versus MCI or healthy controls 
category or finding AD progression biomarkers progression.  
One can reliably classify AD patients and controls in the first group. Most studies revolve 
around temporal mesial lobe (MTL) structures. Many volumetric MCI studies measure 
hand-traced ROIs of specific MTL structures and most of them focus on the hippocampus. 
The majority of published studies indicate MCI patients have less hippocampal volume than 
cognitively intact controls (Becker et al, 2006; Kantarci et al, 2002), and AD patients have less 
volume than those with MCI (Wolf et al, 2004).  
Other studies show average entorhinal cortex volume in MCI patients is decreased 
compared with cognitively intact controls. Cross-sectional ROI studies have shown that the 
hippocampal and entorhinal volumes (Juottonen et al, 1999; Xu et al, 2000) can reliably 
differentiate AD subjects from normal older adults. Although some researchers claim that 
the precision of differentiating MCI from normal controls and MCI from AD is substantially 
less accurate when using hippocampal volume (MCI vs controls: sensitivity = 52– 80 % and 
specificity = 79–80% ; MCI vs AD: sensitivity = 45–60 % and specificity = 80%) than when 
using entorhinal cortex volumetry (Xu et al, 2000; Du et al, 2001; Kantarci et al, 2002), they 
concluded that, given the ambiguity imposed by the  boundaries of the entorhinal cortex, it 
is easier to make these measurements in the hippocampus. Which structure is the more 
powerful discriminator to distinguish MCI patients from normal controls is currently being 
debated. Some studies side with the hippocampus and others with the entorhinal cortex 
(Pennanen et al, 2004).  
The second group of studies is made up of longitudinal research based on disease 
progression. Two hypotheses have emerged: the degree of atrophy progression and the 
basal atrophy found in AD patients.  
Several longitudinal studies have examined the relationship between the brain atrophy rate 
and its progression from MCI to AD. They have found significant group differences 
between MCI patients who progress to AD versus those who do not rapidly progress. They 
show that the hippocampus shows higher annual rates of atrophy in patients with MCI that 
progress to AD than in those who remain stable (Chetelat et al, 2005; Apostolova et al, 2006; 
Jack et al, 2004). Others have found that entorhinal cortex atrophy rate, but not 
hippocampus, is faster for individuals progressing to AD (Stoub et al, 2005). Moreover, 
other studies have shown that not only mesial temporal lobe regions show greater atrophy 
linked with progression towards AD, but also some cortical structures, such as posterior 
cingulum, precunneus or temporal medial lobe (Jack et al, 2004; Jack et al, 2005; Chetelat et 
al, 2005).  
Several studies have examined the accuracy of a single baseline brain MRI in predicting the 
progression towards AD, or stability, using a longitudinal clinical status follow-up. Studies 
using VBM for whole-brain analysis also find that a lower hippocampal baseline predicts 
progression towards MCI (Whitwell et al, 2007; Chetelat et al, 2005; Bozzali et al, 2006). 
Others studies using manual tracing methods have failed to replicate this association and 
report the entorhinal cortex as a more sensitive predictor of progression (de Toledo-Morrell 
et al, 2004; Stoub et al, 2005).  
Investigations using VBM have identified areas outside the mesial temporal lobe in which 
lower baseline volume in certain areas is related to later progression to MCI. These areas are 
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fusiform gyrus (Whitwell et al, 2007; Chetelat et al, 2005), medial and inferior frontal regions 
(Whitwell et al, 2007; Bozzali et al, 2006) and the posterior cingulate and precuneus ones 
(Whitwell et al, 2007; Hamalainen et al, 2007).  
To summarize, it is in the last decade when we have been able to have an accurate idea 
about the structural brain changes in MCI as well and its progression towards AD. Those 
structural changes are multiple. Hippocampal atrophy is important, but there are also other 
important cortical biomarkers. Atrophy is more diffuse than one would expect, but 
pinpointing the specific regional areas of atrophy can be useful in the diagnosis of AD and 
differential diagnosis with other types of dementia. VBM is a technique which can help in 
identifying the regions of atrophy.  
Nevertheless it is important to take into account that all these studies are population ones, 
so none of them serves as an individual maker. Though reliable whole brain measurements 
can be accomplished with authomatized methods there is no way yet to know which MCI 
patients will evolve into AD. However these structural ancillary tests are clinically useful in 
combination with neuropsychological testing, augmenting significantly the prognosis 
accuracy.  
4. Functional magnetic resonance imaging (fMRI)  
It can be described as a non-invasive form (it does not require the injection of a paramagnetic 
contrast) of MRI. It measures the oxygen consumed by certain brain areas when they are 
challenged with specific stimuli or tasks. This technique has got a high spatial resolution and a 
rather acceptable temporal resolution too. Its major inconvenience is its high sensitivity to 
small head movements. It is carried out taking brain images during a specific activity and in 
basal state. Basal state activity is subtracted from the specific task activity to yield the specific 
brain areas where blood flow has increased due to the specific activity tested.  
fMRI physical foundation relies on the inherent magnetic properties of blood. Red blood cells 
(RBC) have a haemoglobin molecule which has an iron (Fe) atom in its centre. Oxygen binds to 
haemoglobin yielding oxihaemoglobin and haemoglobin configuration changes when oxygen 
is delivered to tissues (deoxihaemoglobin). Both oxihaemoglobin and deoxihaemoglobin have 
different paramagnetic properties. Deoxihaemoglobin will create an in-homogeneous 
magnetic field around itself which will lead to a decreased signal. In other words, when there 
is less deoxihaemoglobin (and more oxihaemoglobin) due to increased activity and subsequent 
increased blood flow and associated oxygen concentration within a specific area, there will be 
a greater signal. Blood oxygenation dependent level (BOLD) gives a variable signal intensity 
between stimulus and resting state. BOLD signal relies upon the different magnetic 
susceptibility of oxyhaemoglobin and deoxyhaemoglobin (Westbrook, 2000).  
Task testing is prepared according to paradigms. There is a huge variety of paradigms 
depending on the task. Broadly speaking these paradigms are classified into two main 
groups: “block design” or “event-related”. The former are characterized for stimulus 
presentation for a longer time while in the latter group they are presented for a shorter time 
and in an alternating fashion.  
Numerous studies have shown activation during memory tasks in the anterior hippocampal 
region in both healthy older adults and young people. This activation has a lesser extension 
in healthy older adults. On the other hand healthy young adults exhibit a greater activation 
of the prefrontal cortex and a lesser parietal cortex activation in comparison with older 
adults (Sperling, 2003b).  
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AD patients show a consistent decreased activation in hippocampal and parahippocampal 
areas in comparison with healthy controls (Pariente, 2005). Dickerson et al (2004) suggested 
the cognitive deterioration degree could be inferred from the hippocampal activation at the 
time of fMRI basal scanning; the more hippocampal activation, the greater the deterioration. 
Interestingly, an increased activity in some neocortical regions has also been described 
(Sperling, 2003). This may be understood as a hippocampal failure compensatory 
mechanism. In fact these frontal regions have been labelled “default mode network”, 
implying that AD patients would have difficulty in deactivating them (Buckner, 2005).  
There are few fMRI studies addressing the differences between MCI and healthy adults. 
Moreover, their results show disparity, from mesial temporal lobe hyperactivation 
(Dickerson, 2004) to hypoactivation (Johnson, 2005).  
Dickerson et al (2004) have tried to clarify this issue and they state that whenever there is 
MCI, there is a compensatory hyperactivation, and both the extension and localization of 
this compensatory activity depends on memory tasks demands and memory performance. 
They also affirm that memory starts to fail in advanced MCI stages, which is shown by 
hippocampal hypoactivity. In this way they describe an fMRI activity non-linear trajectory 
in a patient which evolves from MCI to AD, presenting first a hyperactivity phase in pre-
clinical stages followed by an activation decrease. This is what they called “inverse-U shape 
curve” (Sperling, 2007; Dickerson, 2008). This curve poses a problem if it is used as an AD 
biomarker, namely the brain activity pseudo-normalization when people with MCI start 
deteriorating more and at that moment they show a loss of the MCI characteristic 
hyperactivation. They conclude that if there is minimal clinical symptomatology and little 
atrophy of the mesial temporal lobe for a given degree of hyperactivation and more clinical 
symptomatology with greater mesial temporal atrophy for the same degree of activation, we 
are in the ascending and descending parts of the inverse-U shape curve.  
Johnson et al (2004) used a paradigm with repetitive presentation of faces to prove MCI 
patients do not show the same slope of decreasing hippocampal activity than in healthy 
older controls. This suggests a certain disruption of this adaptive response in the medial 
temporal lobe.  
Dickerson (2008) stated the direct linear relation between the clinical deterioration and the 
extension of activity (measured as a function of the number of activated voxels) detected by 
fMRI both in hippocampus as in parahippocampus. Thus, a greater clinical deterioration 
correlates with a greater activity extension in the mesial temporal lobe which, in turn, 
correlates negatively with the degree of hippocampal atrophy.  
Amongst those studies where different patient groups have been compared (healthy ones, 
very mild MCI, MCI and AD), Celone et al (2006) stands out because of the strong 
correlation they found between the degree of preserved memory and the activity of mesial 
temporal areas and deactivation of precunneus and parietal cortex, using always a “default-
mode network” approach.  
5. Diffusion tensor imaging (DTI)  
This technique is also known as diffusion MRI. Its underlying physical basis relies upon 
detection and quantification of the random movement of water known as the Brownian 
movement. Molecules undergoing the Brownian movement follow a chaotic route due to 
continuous impacts against other particles in their environment and their speed is directly 
proportional to the system temperature.  
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Even though the system displacement induced by a single hydrogen molecule cannot be 
appreciated, the impacts of a great number of them generate a significant and quantifiable 
displacement of a chaotic nature. However it is possible to calculate the distance run by a 
particle in a given time through the formula: R=√6 D τ. D is the molecule diffusion 
coefficient, which is dependent on the temperature, while τ is the time interval. In biological 
tissues D is not the only cause of molecular movement since microcirculation, amongst other 
variables, throughout the capillary net has a diffusion increase net effect. This is the reason 
the term apparent diffusion coefficient (ADC) is used.  
When the diffusion in a structured system, such as the brain, is quantified, molecules 
displacement is limited by physical barriers. The latter make the displacement dependent 
upon direction (anisotropy). In a system without barriers a particle undergoing the 
Brownian movement can displace freely in any direction, with an isotropic diffusion. 
Whenever there are physical barriers, such as a membrane or axonal fibres, the particle loses 
movement freedom and the diffusion is therefore restricted (anisotropic).  
A set of DTI images permits the identification of a predominant direction of diffusion 
(anisotropy). The processing of diffusion values is carried out through a structure called 
tensor. A tensor can be defined as a set of co-existing magnitudes dependent upon direction 
and coordinates.  
Tractography permits the reconstruction and 3D visualization of the neuronal column 
structures. If is applied to white matter axon fibres, it provides information about 
connectivity and fibre deviations caused by tumours and infarcts (Martí-Bonmatí, 2008; Le 
Bihan et al, 2001; Melhem et al, 2002).  
In short, MRI water diffusion measurements include those images weighted in diffusion 
(DWI) and tensor diffusion (DTI). DWI provides a mean without direction (isotropic) of 
tissue water diffusivity. DWI is described in terms of ADC. ADC increases reflect neuronal 
loss and increased extracellular space, where water diffusion is faster, and it is an indirect 
indicator of grey or white matter integrity. DTI can be understood as an index of tissue 
permeability difference in different directions (anisotropic) and it is measured in terms of 
mean diffusivity (MD). Another important measurement to take into account is the 
anisotropic fraction (AF). AF is very sensitive in the evaluation of the microstructure 
integrity of the white matter. AF is obtained measuring water diffusivity along white matter 
long tracts (Ries et al, 2008).  
The use of diffusion techniques is justified because of the AD ethiopathogenic mechanism, 
e.g., β-amyloid depositions and neurofibrillary tangles. They seem to interfere with 
neuronal function at early stages producing a cascade of ultra-structural changes in axons. 
The resulting damage affects axonal transport, microtubules structure, neurofilaments and 
the integrity of the myelin sheath (Englund, 1981). All of these factors produce 
microstructural changes in the white matter which, in turn, affect the water protons 
diffusivity, a parameter measurable by DTI. This technique has the advantage of being very 
sensitive in detecting microstructural abnormalities, something not revealed by volumetric 
measurements. 
The loss of tissue organization causes a decrease in anisotrophy (or its correlate, AF). It is 
assumed that reduced water diffusion parallel to axonal tracts is indicative of axonal 
degeneration, disruption and partial breakdown of cytoarchitecture (Beaulieu, 2002) or 
demyelinating processes (Song et al, 2002), which modifies AF. 
We should focus on the corpus callosum (CC), the largest white matter structure in  
the brain. The CC provides inter-hemispheric communication and anterior-posterior 
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connections which link cortical association areas. CC anisotropy decreases with age. 
Progressively reduced AF has been reported as part of the normal aging process (Sullivan et 
al, 2010). This AF decrease seems to follow an anterior-posterior gradient. The genu has a 
lower AF compared to the splenium. Several major white matter fibre bundles, including 
those connecting to the hippocampal structures, pass through the genu of the CC (Serra et 
al, 2010).  
Anatomical localization of AF reductions in amnestic MCI (aMCI) seems to be a robust 
finding across a variety of approaches. Thomann et al (2006) found an AF reduction in the 
rostral subregions and anterior body of the CC in MCI patients compared with healthy 
controls using region of interest (ROI) methods. Similarly Wang et al (2009) and DiPaola et 
al (2010), using voxel based morphometry (VBM), identified a density reduction in the genu 
in aMCI patients compared with healthy controls. Other researchers like Ukmar et al (2008), 
Cho et al (2008) or Parente et al (2008) found an AF reduction in MCI patients in the CC 
splenium. The splenium of the corpus callosum, crux of the fornix (Zhuang et al, 2010) and 
the cingulum were sensitive discriminators to differentiante between aMCI and normal 
subjects (Chua et al, 2009). Ortiz Alonso et al (2000) found a volume reduction of the 
anterior body, mid body and isthmus of the corpus callosum in a homogenous group of 
moderately advanced AD compared with healthy controls.  
Several theories have been proposed to explain the early involvement of frontal white 
matter in MCI. The pattern of white matter integrity disruption tends to follow an anterior-
posterior gradient with greater damage noticeable in posterior regions in AD and MCI. The 
aMCI group showed significant macrostructural atrophy only in the anterior CC section. In 
the mild AD group this atrophy extended to posterior CC subsections and was accompanied 
by anterior and posterior microstructural modifications (Di Paola et al, 2010). 
It has been recently suggested that myelin breakdown is an important component of the 
illness process in AD (Bartzokis, 2004; DiPaola et al, 2010). According to this hypothesis late 
myelinating fibers should be more susceptible to myelin breakdown. This may constitute an 
alternative mechanism which may explain AD cortical progression in the direction opposite 
to myelination (Braak and Braak, 1997). Wallerian degeneration affects the posterior CC sub-
region that gets afferent axons directly from those brain areas primarily affected in AD 
(temporoparietal regions). However the myelin breakdown process might affect the late 
myelination of the  CC subregion, causing changes in the CC genu at early stages of the 
disease (DiPaola et al, 2010). 
 
 
Fig. 2. Coronal, sagital and axial planes DTIs showing AF differences between patients with 
MCI and controls.  
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The controversial results concerning CC regional atrophy are most likely due to the methods 
adopted in various studies, such as different criteria used to select patients, different stages 
of the illness or variation in the number of participants. Those investigators who found that 
the genu was more adversely affected thought that earlier affectation of late maturing 
regions might be responsible, whereas others who found that the splenium was more 
affected said it might be due to the overall degenerative pattern occurring in the posterior 
circuitry of the temporal parietal areas. 
A positive correlation between AF values and MMSE scores has been demonstrated in 
several studies, arguing in favour that white matter degeneration has an impact in cognitive 
performance (Bozzali, 2002; Ukmar et al, 2008; Ortiz-Terán et al, submitted) Other studies 
(e.g., Sullivan et al, 2010) found a correlation between AF decline in the CC with 
performance on the alternate finger tapping test, which is a test of inter-hemispheric 
communication transference.  
DTI is more used nowadays for correct identification of dementia subtypes.  
6. Magnetic Resonance Spectroscopy (MRS)  
MRS is used to measure the levels of different metabolites in body tissues. It detects and 
quantifies resonance signals of certain molecules present at much lower concentrations 
(approximately 10-3 mol/gtissue) than water ones (circa 55 mol/gtissue). The metabolic profile 
of a concrete region within a specific organ can be obtained through a single voxel MRS 
(SVMRS) or through multivoxel MRS imaging. SVMRS provides a metabolic information 
average score within the selected voxel while multivoxel MRS provides, within a unique 
image acquisition, various molecular images which indicate the spatial distribution of 
different metabolites (Martí-Bonmatí, 2007).  
The major drawback of SVMRS is the lack of spatial information, though the magnetic field 
homogenization is excellent and, consequently, so is its spectral resolution. On the contrary, 
multivoxel MRS yields spatial distribution information of different metabolites but its 
magnetic field homogenization is rather complicated since the brain areas are bigger and 
their magnetic susceptibility differences greater. Hence the characterization of a given 
specific volume is more precise with SVMRS but multivoxel MRS generates additional 
molecular information about surrounding areas. The latter provides more information about 
the heterogeneity of the lesion, analyzes peripheral infiltrations and allows comparisons 
with contralateral areas (Martí-Bonmatí, 2007).  
The most common CNS metabolites measured with MRS are (1) N-acetyl-aspartate (NAA), a 
neuronal marker localized in neurons and axons, (2) choline (Cho), a marker which indicates 
membrane changes, (3) Creatine/phosphocreatine (Cr/PCr), an index of energetic 
metabolism, (4) lactate (Lac), a final product of glycolisis generated because of oxidative 
metabolism failure which is found both in intra and extra-cellular compartments, but never 
found in healthy tissues, (5) myoinositol (mI), mainly found within astrocytes where it 
regulates the cell volume, (6) lipids (Lip) and polypeptides, mostly in myelin sheaths and 
cell membranes and (7) glutamine (Gln) and glutamate (Glu), important neurotransmitters 
involved in multiple synaptic processes which give complex signals because of their 
ubiquity, scalar coupling and multiple complexes therefore posing a real challenge for their 
quantification.  
In short, MRS is the only available technique for obtaining fast and simultaneous metabolic 
information in vivo and different molecular images within a single image acquisition. It is a 
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reliable method for clinical molecular follow-up and studying therapeutic effectiveness in 
different diseases.  
 
 
Fig. 3. MRS in Alzheimer Disease  
Axial T2-weighted images from an AD patient (L, left) and a healthy control (R, right). These 
images show the left parietotemporooccipital region where the spectra was acquired, and 
the results are shown just below. Please note the differences between the two subjects in the 
mI.  
With regards to AD, and from the early nineties, MRS has become a frequently used 
technique. The typical 1H-MRS includes the following peaks: NAA, Cr/PCr, Cho containing 
compounds, Glu and mI. Most authors have opted for following up AD progression using 
voxels in the medial temporal lobe. However Kantarci et al (2002) states that from a biologic 
standpoint there is evidence from MR imaging, fluorine 18 (18F) fluoro-deoxy- glucose PET, 
amyloid ligand PET, and fMRI studies that the posterior cingulate gyri (bilaterally) and the 
inferior precuneate gyri exhibit atrophy, decreased metabolism, amyloid deposition and 
deactivation early in the course of AD (Whitwell et al, 2007; Petrella et al, 2007; Chetelat et 
al, 2003). Moreover, the quality and reliability of 1H MR spectra from these voxel locations 
are superior to those from the medial temporal lobe because of the close proximity of the 
medial temporal lobe to the skull base, an area susceptible to magnetic artefacts. 
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Besides of the voxel location, NAA has been considered a prominent candidate for AD 
investigation and diagnosis since it is localized only in neurons and absent in glial tissue in 
mature brains (Simmons et al, 1991). Hence NAA is a general marker of neural integrity. The 
first ever described finding in relation to AD was a decrease in NAA concentration in the 
brain (Miller et al, 1992), a reduction positively correlated with the density of senile plaques 
and neurofibrillary tangles (Klunk et al, 1992). Because NAA is a neuronal metabolite, the 
reduction of NAA levels in patients with AD is the result of loss of neuronal components, 
neuronal function disruption, or both; these phenomena are strongly associated with 
increasing neurofibrillary degeneration. On the basis of the correlation between 
mitochondrial ATP production and NAA level, NAA production within the neuron is 
thought to be related to mitochondrial function (Bates et al, 1996). 
Both Shonk et al (1995b) and Kantarci et al (2000) described bilateral temporoparietal 
increase of Cr and mI concentrations as well as the mI/NAA ratio in AD. These authors also 
found significantly elevated mI and Cr concentrations in the parietal region in early AD 
stages while NAA remained largely unchanged. Based on these findings they suggested mI 
and Cr abnormalities could be detected with MRS prior to abnormalities in neocortical NAA 
(Shonk et al, 1995b). Nevertheless, only the mI/NAA ratio was capable of classifying AD 
and healthy controls without any overlap between the groups (Panertti et al, 1998). Kantarci 
et al (2002) found a sensibility around 82% and a specificity ranging from 80 to 90% for MRS 
in classifying AD, clinically defined, and healthy controls. 
The observation of an increased mI concentration not coupled with a cortical NAA decrease 
had already been reported in a group of AD patients with a low MMSE score and, also, in a 
group of Down’s syndrome patients in the pre-dementia phase (Huang et al, 1999). 
Therefore mI, but not NAA, showed an inverse linear correlation with MMSE scores (Huang 
et al, 2001).  
The most plausible up-to-date explanation for the increased levels of mI in the brain of AD 
patients is the contribution of the glial component. Glia contains much higher 
concentrations of mI than neurons (Glanville et al, 1989) and gliosis may cause the increase 
in mI found in AD patients (Huang et al, 2001). This may suggest that glial proliferation is a 
sensitive measure of AD before neuronal loss, the latter reflected by NAA (Fig 3). 
Shonk and Ross (1995a) had previously supported the aforementioned hypothesis by 
showing that adults with Down’s syndrome exhibited a significant elevation of mI before 
the onset of dementia without any concomitant reduction in NAA. On the other hand, 
cholinergic receptors in the CNS are believed to act in part through the phosphoinositide 
pathway (Honchar, 1990; Kennedy, 1990). Jolles et al (Jolles, 1992) showed a reduced activity 
of the inositol polyphosphate enzyme phosphatidyinositol kinase and postulated a specific 
defect in the inositol polyphosphate cascade in AD to such a degree that cholinergic activity 
could be affected. Ross et al (2005) summarized this evidence proposing that alterations in 
mI must have consequences for enzyme equilibrium and the metabolite concentrations in 
the inositol polyphosphate cascade. Accordingly, altered cholinergic sensitivity could be 
expected. 
During the last decade 1H MRS in vivo studies have consistently indicated NAA decreases 
and mI increases in patients with AD and aMCI (Valenzuela and Sachdev, 2001). The 
strongest association between MRS and anatomopathologic findings was observed when 
two metabolite ratios were combined to yield the NAA/mI ratio; this result suggests that 
NAA and mI have complementary roles in predicting AD pathology. As previously said, 
NAA is located primarily in neuron bodies, axons, and dendrites. Therefore, it is a sensitive 
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marker for neuronal density or viability. In patients with amnestic MCI mI/Cr ratios are 
elevated but NAA/Cr ratios are only mildly decreased. These findings suggest that the 
mI/Cr ratio increase happens earlier than does the decrease in NAA/Cr ratio decrease in 
AD (Parnetti et al, 1997).  
In a recent 1H MRS study, Cho/Cr ratios longitudinally increased in patients with amnestic 
MCI who progressed to AD (Kantarci et al, 2007). In contrast, Cho/Cr ratios decreased in 
patients with amnestic MCI who remained stable. 
Wang et al (2009) described: a) Hippocampal mI/NAA increases were significantly larger 
than those in the posterior cingulate area (an area with a recognized relationship in the 
pathological progression of AD); b) Hippocampal and posterior cingulated mI/NAA 
together provided valuable discrimination to differentiate AD, MCI and control groups and 
c) there were significant correlations between mI/NAA in the hippocampus and the 
posterior cingulate area and MMSE scores. The posterior cingulate area suffered later 
neuropathological and spectroscopic changes.  
A reduced NAA was found in the right hippocampus (p = 0.01) in MCI patients while 
increased mI was reported in the left hippocampus (p = 0.02). mI/NAA ratios were higher 
in both right (p = 0.03) and left (p = 0.01) hippocampi of MCI subjects (Franczak et al, 2007). 
Greater mI concentrations have also been found in patients with MCI (Godbolt et al, 2006; 
Kantarci et al, 2000). Neuropathological studies of MCI have shown the existence of 
hippocampal damage. This goes along with the hypothesis that MCI is a transitional state 
between normal aging and AD. A recent study found reductions in NAA/mI ratios in 
presenilin 1 and amyloid precursor protein mutation carriers who have a nearly 100% risk of 
developing AD (Godbolt et al, 2006). Metastasio et al (2006) observed a significant a 
NAA/Cr decrease in the parietal white matter in a group of five patients who developed 
AD after being diagnosed with MCI. This was replicated by Pilatus et al (2009). Modrego et 
al (2005) identified the occipital cortex as the most sensitive area for NAA/Cr ratios. To 
summarize, MI/NAA ratio may be a useful biomarker for diagnosing MCI and it may help 
to commence early treatment in affected individuals (Franczak et al, 2007).  
In AD patients NAA levels may also return to normal within the first 6 weeks of treatment 
with donepezil (Krishnan et al, 2003). NAA is not just a marker for neuronal function and, 
possibly, neuronal mitochondrial function, but can also be a surrogate marker to evaluate 
progression and decline in neuronal integrity during the transition period from MCI to 
dementia.  
Other attempts to evaluate alternative metabolites have been done. Glu and Gln are 
decreased in the cingulate gyrus in AD patients (Antuono et al, 2001). However, the precise 
role of glutamate excitotoxicity in the development of MCI and AD remains largely 
unknown.  
In short, and in spite of the difficulties posed by the voxels localization in the mesial 
temporal lobe, this seems to be the best place to accurately discriminate between MCI and 
AD as well as measuring MCI progression. The most relevant metabolites in MCI and AD 
are mI and NAA. They also allow to correctly classify the patients between those two 
groups and to evaluate their response and treatment and disease progression.  
7. Single-photon emission computed tomography (SPECT)  
Brain SPECT allows the study of regional cerebral blood flow (rCBF), which correlates at 
rest with the regional consumption of glucose and reflects neuronal activity. Thus, the rCBF 
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indirectly reflects neural activity in each brain region, and allows the earlier detection of 
functional abnormalities, preceding the stage of symptomatic disease.  
The tracers currently used in the clinical practice are 99mTc-Hexamethyl-propylene-amine-
oxime (99mTc-HMPAO), which is considered to be the most reliable SPECT method, and 
99mTc-ethyl cysteinate dimer (99mTc-ECD). They enter cells due to their lipophilic character 
and remain trapped because of their conversion to hydrophilic compounds. Their 
incorporation is proportional to rCBF in the first few minutes after injection. Modifications 
in rCBF after injection do not change the initial distribution of the tracer because of its 
intracellular trapping (Farid et al, 2011).  
Both radiotracers have a similar behaviour, being captured in the brain, with a distribution 
pattern corresponding to the rCBF (Koyama et al, 1997). Brain SPECT reveals a specific 
pattern of abnormalities in AD by demonstrating reduced rCBF in the medial temporal, 
superior temporal, parietal, posterior cingulate cortex, and precuneus before becoming 
diffuse and affecting the frontal cortex in advanced stages (Farid et al, 2011). 
SPECT images represent the topography of physiopathologic changes in AD (Fig 4) and it is 
a promising diagnostic tool in the early diagnosis and its differentiation from other 
potentially treated causes of dementia such as normal pressure hydrocephalus or depression 
(Bartenstein et al, 1997). 
 
 
Fig. 4. SPECT in AD. Transversal slices of a 99mTc-ECD SPECT study in a patient with early 
AD. Bilateral temporal hipoperfusion and assymmetrical parietal hipoperfusion, more 
evident on the right cortex, can be seen  
www.intechopen.com
The Clinical Spectrum of Alzheimer’s Disease  
– The Charge Toward Comprehensive Diagnostic and Therapeutic Strategies  162 
Haxby et al (1985) were able to link metabolic function, measured with SPECT, with a 
variety of cognitive and behavioural domains, including memory.  
8. Positron emission tomography (PET)  
In the last decades there has been a progressive advance in the development of techniques able 
to explore neurophysiological and neurochemical processes in humans. Positron emission 
tomography (PET) is a powerful technique allowing the visualization of physiological and 
biochemical changes both in healthy and ill subjects. This type of unique information may not 
be available with structural brain imaging techniques. PET has been useful to elaborate the 
hypothesis of the pathogenesis of AD, in correlating symptoms with their biological markers 
and in studying individuals at increased risk (Giovacchini et al, 2011).  
Glucose is the main energy supply for the brain and its metabolism maintains ion gradients 
and glutamate turnover, and it is related to neuronal function at rest and during functional 
activation Its measurement by [18F]-2-fluoro-2-deoxy-D-glucose (18F-FDG) is based on 
phosphorylation of the tracer by hexokinase, which is the pivotal first step of that metabolic 
pathway. Measurement of regional cerebral glucose metabolism (rCMRglc) using 18F-FDG 
PET has become a standard technique in dementia research (Herholz et al, 2007). FDG PET 
is the approach most efficiently used in AD and MCI diagnosis.  
The visualization of metabolic abnormalities using 18F-FDG PET, reveals similar patterns to 
that of SPECT, with hipoactivity in temporal and parietal neocortex in association with AD, 
detected either by visual inspection or by conventional quantitative analyses selecting 
regions of interest (ROI). 
PET and SPECT studies using SPM-based image analysis methods have replicated 
temporoparietal neocortical hypoactivity findings in AD; moreover, these studies have been 
able to document activity decrements also in the medial temporal region (where the 
neuropathological process occurs first, with greatest severity and in the posterior cingulate 
gyrus and precuneus (Matsuda, 2001). That pattern of hypometabolism has been detected 
even in very early stages of AD (Fig 5) and in subjects at genetic risk for the disorder (Duran 
et al, 2007).  
As AD progresses, the frontal association cortex becomes involved, while cerebellum, 
striatum, basal ganglia, primary visual, and sensorial and motor cortex remain unaltered 
(Mosconi, 2005). Hemispherical asymmetries are often observed, especially at early stages of 
AD and may be attributed to co-morbidity factors (e.g., vascular brain disease) or 
compensatory mechanisms (e.g., neuroplasticity). This in vivo pattern of hypometabolism is 
found in the majority of clinically diagnosed AD patients and in over 85% pathologically 
confirmed AD cases (Mosconi et al, 2010).  
18F-FDG PET is therefore a useful diagnostic tool to identify the cause of dementia and to 
have a differential diagnosis with other diseases, and to determine the neurophysiological 
mechanisms underlying these pathologies. Table 2 shows the characteristic locations of 
hypometabolism according to different types of dementia. (Montz et al, 2002). 
18F-FDG PET is more sensitive than clinical criteria in the detection of AD and in the 
differential diagnosis with other dementias, reaching values of diagnostic accuracy between 
80 and 100%, with sensitivity of 90-96 % and specificity of 67-97% for AD (Gambhir et al, 
2001, Knopman et al, 2001 Silverman et al, 1999).  
It should be noted that this technique has been helpful in diagnosing AD, irrespective of the 
degree of cognitive impairment. In fact, abnormal parietotemporal uptake patterns were  
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Fig. 5. PET in AD. Transversal, coronal and sagital slices of a cerebral 18F-FDG study of a 
patient with mild cognitive impairment. Hypometabolism of bilateral temporal and parietal 
cortex including part of the posterior cingulate gyrus (left dominance) was observed, 
corresponding to incipient AD. 
 
TYPE OF DEMENTIA HYPOMETABOLIC BRAIN AREAS 
Alzheimer’s disease    Parietal and superior/posterior temporal abnormalities; 
bilateral temporoparietal hypoperfusion (frontal lobe 
hypoperfusion may happen in conjuncion with 
temporoparietal hypoperfusion)  
Earliest changes in medial portion of parietal cortex, 
posterior cingulated or retrosplenial region  
Diffuse Lewy body disease Temporoparietal associatedwith occipital hypoperfusion 
Corticobasal degeneration Cortex and contralateral thalamus to the affected limb 
Progressive supranuclear 
palsy 
Motor/premotor frontal cortex, anterior cyngulate gyrus, 
hippocampus, basal ganglia and thalamus 
Frontal dementia Frontal, anterior cyngulate gyrus, anterior temporal lobe,  
hippocampus, basal ganglia and thalamus 
Vascular dementia Irregular pattern of uptake due to strokes 
Parkinson’s disease Frontal-temporal-parietal 
Table 2. 18F-FDG PET pattern of uptake in different types of dementia 
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seen on 18F-FDG PET images obtained in asymptomatic members of families in which a 
familial form of early AD was present. Similarly, asymptomatic subjects with the 
apolipoprotein ε4 allele were found to have significantly less parietotemporal 18F-FDG 
uptake than those without this allele. 18F-FDG PET has also proved useful to follow the 
course of AD patients. A normal PET study indicates that pathologic progression of 
cognitive impairment during a 3-year follow-up period is unlikely to occur. In another 
study, investigators were able to predict the clinical course of patients with mild cognitive 
impairment by using 18F-FDG PET images obtained early in the course of disease 
(Hammoud et al, 2009). 
Few studies have directly compared brain perfusion SPECT and 18F-FDG PET in AD. Ishii et 
al. in 1999 compared 99mTc-ECD SPECT images with 18F-FDG PET images in the same ten 
patients with Alzheimer's disease. 99mTc-ECD SPECT showed a reduction in parieto-temporal 
perfusion in 8 of the 10 patients, whereas 18F-FDG PET showed a reduction in temporoparietal 
metabolism in nine of them. The contrast between the radiotracer uptake in the sensorial and 
motor areas and that in the parietotemporal region was not as great in the ECD images as it 
was in the FDG images (Ishii et al, 1999). Messa et al, in 1994, performed 99mTc-HMPAO 
SPECT and 18F-FDG PET in patients with mild to moderate AD and in healthy control subjects. 
They reported that these techniques had similar abilities for visualizing decreased perfusion 
and metabolism in the temporoparietal cortex and similar diagnostic accuracies (Messa et al, 
1994). In 2002, Herholz et al. showed good correlation between 18F-FDG PET and 99mTc-
HMPAO SPECT for detecting changes in the temporoparietal cortex in mild to moderate AD 
by using voxel-based statistical image analysis (Herholz et al, 2002), although 18F-FDG PET 
demonstrated a more robust differentiation of patients with AD from healthy volunteers than 
did SPECT (Matsuda, 2007). 
The meta-analysis performed by Yuan et al. in 2008 comparing results of 18F-FDG PET, 
SPECT and structural MR imaging to predict conversion to AD in patients with mild 
cognitive impairment, including data from 1112 patients, showed that 18F-FDG PET had 
moderately better concordance with follow-up results for the prediction of conversion. 
Approximately 88.9% of the patients with progressive mild cognitive impairment were 
considered affected by 18F-FDG PET, whereas 84.9% of stable patients had negative 18F-FDG 
PET (Yuan et al, 2008). 
Another method for in vivo assessment of the extent of AD is the use of new radiotracers 
including the amyloid PET tracer Pittsburgh Compound B (11C-PIB) for visualizing fibers 
Aβ (Morris et al, 2009, Kadir et al, 2011) or 2-(1-{6-[(18F-fluoroethyl)(methyl)amino]-
2naphthyl}ethylidene) malononitrile (18F-FDDNP) that has been reported to label not only 
amyloid but also neurofibrillary tangles  (Tolboom et al, 2009), and these methods have 
generated new possibilities for early diagnosis of brain impairments. 
The first attempt to image brain Aβ accumulation in AD was reported by Friedland et al. in 
1997 using a monoclonal antibody fragment labelled with 99mTc for single SPECT. This first 
attempt failed, but it was fundamental for subsequent efforts (Friedland et al, 1997). The 
second used PET, and the report of this work was published in 2002 (Shoghi-Jadid et al, 
2002). The radiotracer used was 18F-FDDNP but had the disadvantage of a limited 
experience worldwide (Klunk & Mathis, 2008). The third study of in vivo Aβ imaging  with 
11C-PIB, was reported in 2004 (Klunk et al, 2004).  
The quantity of radiotracer measured must be proportional to the amount of Aβ in that area 
and there must be sufficient signal-to-noise ratio to detect the tracer when levels of Aβ have 
become clinically significant. There are some published data for PIB demonstrating these 
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properties both in vivo and in post-mortem studies (Klunk et al, 2005, Maeda et al, 2007, 
Wiley et al, 2009). There is no doubt that the validation of an in-vivo Aβ tracer needs in-vivo–
post-mortem correlation study in humans. 11C-PIB has  the advantage of not showing 
significant changes over 2 years during clinical AD (Engler et al, 2006).  
Several tracers including 18F-BAY94-9172 (Wang et al, 2011) (figure 3), 18F-AV-45, 18F-
AH110690, 18F-3′F-PiB, 11C-AZD2995 and 11C-AZD2184 have recently been or soon will be 
used in multi-centre phase II or phase III trials.  
To understand the behaviour of a tracer in neurodegenerative disease, it is important to note 
that the population should include not only patients with AD or healthy controls. Studies on 
populations with mild cognitive impairment, early onset familial autosomal dominant AD, 
Parkinson’s disease, Lewy body disease, fronto-temporal dementia, cerebral amyloid 
angiopathy, prion disease and other atypical dementias and cognitively normal aging 
contribute to our understanding of Aβ imaging with 11C-PIB. A third principle for 
acceptance should be widely available of any Aβ imaging tracer.  
The leading difference between these radionuclides is their decay ‘half-life’. The decay half-
live of carbon-11 is 20 min and that of fluorine-18 is 110 min. The main advantage of carbon-
11 is that it decays so rapidly that sequential imaging studies in the same patient can be 
performed on the same day, thus, a 11C-PIB study can be followed by a study using 18F-
Fluorodeoxyglucose (FDG). This would require two different days with a fluorine-18-
labeled Aβ tracer. However, the 110 min half-life of fluorine-18 allows distribution within a 
2–4 h travel radius. Thus, the need for a good fluorine-18 Aβ imaging tracer is mainly a 
matter of widening the availability. The properties of 11C-PIB appear quite sufficient for 
imaging Aβ with a carbon-11 tracer, so the current goal is to obtain a fluorine-18 tracer with 
similar characteristics to those of 11C-PIB (Klunk & Mathis, 2008).  
To conclude about these two nuclear medicine brain imaging approaches (SPECT and PET), 
SPECT with 99mTc-HMPAO and 99mTc-ECD and 18F-FDG PET are very useful diagnostic 
tools for early diagnosis of AD, even in pre-clinical stages. Posterior cingulated 
hypometabolism, measured with SPECT, may help to predict progression from MCI to AD. 
Some authors have stated that SPECT can be highly accurate in identifying the type of 
dementia (Read et al, 1995). The severity of temporoparietal metabolism impairment, 
measured by FDG PET, is helpful to distinguish those people with a progressive course of 
their condition from those who have a non-progressive course. This is useful for delivering 
MCI prognosis. The development of new radiotracers able to demonstrate the presence of 
Aβ plaques in AD patients, will improve the specificity of those methods. Finally, it is worth 
mentioning these nuclear medicine neuroimaging methods can serve as surrogate markers 
in clinical trials of therapeutic agents (Mueller et al, 2005; Teipel et al, 2006).  
9. Magnetoencephalography (MEG)  
MEG is a non-invasive technique that allows recording the magnetic fields generated by the 
human brain. MEG provides an excellent temporal resolution up to milliseconds, magnitude 
orders better than in other methods for measuring cerebral activity, such as CT, MRI, SPECT 
or PET (Hämäläinen et al, 1993). It generates functional maps with delimitation of cerebral 
structures in the range of few cm and, even, cubic millimeters. Therefore these functional 
maps can be organized both temporal and spatially. MEG signal is generated by 
synchronous oscillations of pyramidal neurons; the MEG detects slightly different features 
of the simultaneous electromagnetic brain activity and MEG power represents the activity of 
a given number of neurons discharging synchronously.  
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Some MEG background activity abnormalities in moderate and severe AD have been 
observed. AD patients show a decrease of MEG coherence values (Berendse et al, 2000). This 
biological marker is accompanied by a slowed MEG activity which becomes evident when 
analyzing the power spectral density of selected frequency bands. In this way, spontaneous 
MEG activity shows increased slow rhythms and reduced fast activity in AD patients 
compared with healthy subjects (Berendse et al, 2000; Fernández et al, 2002; Osipova et al, 
2005).  
It has been proposed that such slowing might be due to an increase in activation of low 
frequency oscillators rather than slowing of existing sources (Osipova et al, 2005). Fernández 
et al (2002) analyzed the presence of low frequency magnetic activity (delta and theta bands) 
associated with AD degeneration. Their results showed that people with AD had a 
significant increase of this type of frequencies in the temporoparietal area greater in the left 
hemisphere. Moreover, the values of low frequency were associated with the cognitive and 
functional state of these patients. Temporoparietal delta activity predicted the scores in 
mental status scales such as MMSE or CAMCOG. Delta activity in right parietal areas 
allowed predicting the functional status (FAST stage). Fernández et al (2006C) replicated 
previous studies stating that temporoparietal low frequency plays a key role in the process 
that leads from MCI to AD. There is a slow and practically linear low frequency activity 
from normal aging to dementia where MCI has an intermediate position. This study, once 
the parietal low frequency was defined as the most relevant feature to characterize these 
patients, carried a follow-up study of the people with MCI. The next step was to find out if 
MCI patients with more marked low frequency had more probability to evolve into AD. 
This group showed that people with MCI and higher parietal delta activity had 3,5 times 
more chance to develop AD (Fernández et al, 2006A). Broadly speaking, from the 
perspective of spontaneous MEG activity, one can say that a tendency towards brain activity 
slowing means a higher risk to develop dementia.  
Fernandez et al (2006B) carried out a detailed analysis of spontaneous MEG activity spectral 
changes where the frequencies spectrum 2-60 Hz was subdivided “microscopically” in 2 Hz 
bands. The relative power of these micro-bands was then calculated. This approach served 
to overcome the difficulties in comparing data with previous literature, since there is some 
variation in establishing the limits of traditional EEG bands. A narrow temporoparietal 20-
22 Hz band differentiated clearly the AD group from healthy elderly people and was 
correlated with the cognitive status.  
MCI is an ideal target for this type of studies because the rate to progression to AD in 
healthy elderly people is about 1-2 % yearly, but in the MCI group this rate is 10-15 %. In 
fact AD and MCI share some characteristics which make difficult to establish a dividing line 
between both of them. Essentially anyone diagnosed with MCI will exhibit some cognitive 
impairments, specifically in the memory domain, that can be measured objectively but allow 
this patient to carry out a normal lifestyle. Therefore he cannot be diagnosed as suffering 
from dementia. Because of this fact many authors consider MCI as an intermediate or 
transitional state between normal aging and AD.  
Once MCI was chosen as a target, we did a first study following-up a series of normal 
elderly people for two years. We realized those patients developing MCI had a MEG activity 
reduction in medial temporal regions during a memory task compared with those who had 
normal aging (Maestú et al, 2006). Along this line Poza et al (2007) evaluated the 
discriminative power of five measures extracted from the MEG power spectrum. The best 
one of them was the spectral mean frequency (sensitivity = 85%, specificity = 85.71%), thus 
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confirming the presence of spectral slowing in AD. Spectral changes can also be 
characterized in terms of ratios between powers in different frequency bands. In a later 
study Poza et al (2008) showed that a ratio of relative power in fast bands (alpha, beta and 
gamma) and slow ones (delta, theta) had a 75% sensitivity and a 95% specificity for the same 
purpose. A comparison of spectral median frequency with various nonlinear measures 
indicated median frequency was the single best discriminator between AD patients and 
controls (Hornero et al, 2008).  
Another important issue during basal MEG, as well as during basal EEG, is brain 
complexity. Some authors have found a global decrease in irregularity and complexity in 
AD during basal (rest) MEG recordings (Poza et al, 2006; Gomez et al, 2006). However, the 
loss of complexity has been only proven in the high frequencies when a detailed spectral 
analysis in several frequency bands was performed.(van Cappellen et al, 2003).  
Other approaches have focused on analyzing functional connections rather than local 
abnormalities in AD. A decrease of coherence values in the alpha band (Franciotti et al, 
2006) and a general decrease of coherence in all frequency bands (Berendse et al, 2000) have 
been described. A reduced level of synchronization has also been reported in the upper 
alpha, beta, and gamma bands of AD patients in comparison with controls suggesting a loss 
of functional connectivity (Stam et al, 2002). Using resting MEG some authors have shown 
functional connectivity in AD is characterized by specific changes of long and short distance 
interactions in several frequency bands (Stam et al, 2006). Decreased levels of functional 
connectivity point towards the relationship of AD with an abnormal function of the large 
scale brain networks.  
Recently Fernández et al (2010) have shown AD non-linear analysis is characterized by a 
reduced complexity and connectivity. They calculated Lempel-Ziv complexity (LZC) values 
and found that MCI patients exhibited intermediary LZC scores between AD patients and 
healthy controls. A combination of age and posterior LZC scores allowed AD-MCI 
discrimination whereas no LZC score allowed MCI-healthy controls discrimination. AD 
patients and controls showed a parallel tendency towards diminished LZC scores as a 
function of age, but MCI patients did not exhibit such “normal” tendency. Accordingly, 
anterior LZC scores allowed MCI-healthy controls discrimination for subjects below 75 
years. People with MCI exhibited a qualitatively distinct relationship between aging and 
complexity reduction, with scores higher than controls in older individuals. This fact might 
be considered a compensatory mechanism in MCI before fully established dementia.  
A third type of MEG studies is through brain synchronicity. There is increasing evidence 
that ubiquously distributed neural systems may communicate through synchronization of 
their activity. Synchronization here refers to the existence of a consistent relationship 
between activity patterns of two or more spatially separated neuronal groups. 
Synchronization can be defined at action potentials level or at oscillatory activity one. 
Synchronization in different frequency bands has been associated with various cognitive 
functions and the integration of information in the healthy brain (Stam, 2010).  
Using the synchronization likelihood as a measure of functional connectivity, a loss of 
functional interactions between brain regions in alpha, beta and gamma bands was 
demonstrated in AD patients (Stam et al, 2002). In the same study coherence analysis did not 
show any significant differences between AD patients and controls, suggesting that 
nonlinear coupling might play a role. In a further analysis of the same data, van Cappellen 
et al (2003) showed that a neural complexity measure was increased in AD in both delta and 
theta bands, whereas the multichannel correlation dimension was increased in the beta 
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band; these results argue against a simple concept of ‘loss of complexity’ in AD and suggest 
a pattern of decreases as well as increases of functional connectivity in different frequency 
bands. This pattern was subsequently elucidated in another study showing a loss of mainly 
long distance left hemisphere functional connectivity in low alpha and beta bands, and an 
increase in parietal theta and occipito-parietal beta/gamma connectivity in AD patients 
compared to controls (Stam et al, 2006). The preferential loss of left hemisphere connectivity 
is interesting because some researchers (Osipova et al, 2003; Fernandez et al, 2006) have 
suggested a left hemisphere vulnerability rather characteristic. The increased connectivity in 
occipital and parietal areas is remarkable. Possibly, these changes could also reflect a kind of 
compensatory mechanism. Coherence analysis of the same data showed a roughly 
comparable pattern of changes. Furthermore, inter-hemispheric alpha band synchronization 
likelihood was significantly correlated with the MMSE score, suggesting the functional 
significance of these resting-state measurements. 
A problem of functional connectivity studies based upon correlations between raw EEG or 
MEG signals is a single source is often picked up by many sensors, giving rise to spurious 
correlations. This volume conduction problem can be solved by special measures such as the 
phase lag index, which eliminates possible contributions from common sources, and reflects 
more accurately true interactions between distributed brain areas, reconstructed functional 
brain networks (Stam et al, 2007). This approach allows the classification of networks on a 
scale ranging from completely ordered to completely random. It was shown that in the 
alpha band brain networks in AD were more random than brain networks of healthy 
controls. Finally, using a modeling approach, it could be shown that the process that gives 
rise to abnormal brain networks in AD probably attacks critical connections between 
networks hubs preferentially. 
Lastly, cognitive function studies through magnetic evoked potentials have been widely 
used both in MCI and AD. The MEG activity pattern during cognitive task is significantly 
altered (Maestú et al., 2001). A study showed greater MEG parietotemporal activity in the 
left hemisphere during a memory task in healthy elderly people compared with AD 
patients. The latter showed a reduction of MEG activity accompanied by an anomalous 
localization in frontal areas. This activation profile can predict performance in cognitive 
tests such as the MMSE or CAMCOG, as well as with daily life functional outcomes. Thus a 
lesser parieto-temporal activation during a memory task is associated o lower scores in 
cognitive tests, what makes MEG a functional neuroimaging technique useful for diagnosis.  
In combining MEG with volumetry data obtained from MRI, we have found a direct 
relationship between hippocampal atrophy with both an increased magnetic activity of low 
frequency (Fernández et al, 2003) and a decreased magnetic dipoles during a memory task 
(Maestú et al, 2003).  
A relevant aspect is studying those MEG normal changes which are part of normal aging. 
We have studied elderly people at different ages and we have found a cortical 
reorganization as age progresses (Maestú et al., 2004). Besga et al (2010) also found that 
hippocampal volume reduction allowed the discrimination between AD and MCI patients 
as compared with controls. The percentage of correct classification was 91.3% when AD 
patients versus controls were compared, and 83.3% in the case of MCI versus controls. MEG 
data showed that AD patients exhibit higher theta and delta activity than MCI and controls. 
Such higher activity was significant in parietal, temporal, and occipital areas. Left parietal 
theta classified correctly MCI patients (vs controls) in 78.3% of the occasions. Right occipital 
theta and the left parietal delta allowed correctly discrimination of AD patients (vs controls) 
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at a 81.8% rate. Left parietal theta discriminated between AD and MCI in 56.6% of the 
occasions. In addition, the combination of both techniques significantly improved the rate of 
correct classification, thus indicating that a multidisciplinary perspective of techniques may 
improve the diagnostic capabilities (Besga et al, 2010).  
Osipova et al (2006) used source estimation of ongoing MEG oscillations to detect changes in 
subjects with MCI. In this study, the distribution of alpha sources did not differ between 
subjects with MCI and healthy elderly controls. Maestú et al (2006) suggested MEG can 
provide useful information about the risk of developing MCI. They recorded MEG during a 
memory task in 15 healthy subjects. Five of these subjects developed MCI after two years. 
These subjects were characterized by abnormal low frequency activity in the left temporal 
lobe in the initial recording. The MEG mean frequency power spectrum in MCI subjects was 
decreased compared to healthy controls, and increased compared to Alzheimer patients 
(Fernández et al, 2006 A). This suggests once more MCI is, in some respects, an intermediate 
state between health and AD. Furthermore, an average decrease of 0.17 Hz/year of the 
mean frequency in healthy subjects was shown. Slowing of MEG in MCI could be related to 
the risk of developing AD.  
10. Conclusion  
Along this chapter we have highlighted some issues in relation to MCI. MCI is less known 
from the brain imaging point of view than AD. The high chance to progress from MCI to AD 
indicates the need to do more studies on this domain. MRS and those neuroimaging 
techniques based on neurophysiological measurements, e.g. MEG, can throw light on this 
area.  
Brain imaging techniques have not reached a point yet where they can provide the 
confirmatory diagnosis of AD. However the likelihood of suspicion of AD can be enhanced 
by these methods. Table 3 summarizes these brain imaging techniques in AD and MCI.  
 
Neuroimaging 
technique 
Strengths  Limitations  Comparison 
AD-MCI 
CT  Low cost, high 
availability  
Relative poor 
resolution  
Poor differentiation 
grey matter-white 
matter  
Does not add  
MRI  Extensive use, high 
availability  
Poor correlation with 
changes in function 
and metabolic 
findings  
Volumetry and ROI 
volumetry can be 
useful, even more so 
longitudinally  
fMRI  Gives insight into 
cognitive 
performance  
Conflicting results  Can be useful as well, 
but results 
interpretation may be 
difficult  
DTI  Can assess 
structural 
connectivity  
Utility not proven  AF reductions in aMCI 
is a robust finding  
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Neuroimaging 
technique 
Strengths  Limitations  Comparison 
AD-MCI 
Spectroscopy  Provides 
information about 
brain chemical 
content  
Utility not proven  NAA and mI may 
measure progression 
from MCI to AD  
SPECT  Low cost compared 
with PET  
Mediocre resolution 
Radiation exposure  
Limited utility  
PET  Can detect 
metabolic changes 
in AD  
Expensive  
Lack of availability  
Most useful tool to 
differentiate AD from 
MCI, so far   
PET-amyloid  Detects most 
specific metabolic 
change linked to 
diagnosis  
Difficult interpretation 
as neurometabolic 
changes may antecede 
disease  
Can be a risk 
biomarker, but results 
interpretation may be 
difficult  
MEG  Gives insight into 
cognitive 
performance  
High temporal 
resolution  
Very expensive  Some usefulness for 
this purpose has been 
demonstrated  
CT = computerized tomography; MRI = magnetic resonance imaging; fMRI = functional magnetic 
resonance imaging; DTI = diffusion tensor imaging; SPECT = single-photon emission computed 
tomography; PET = positron emission tomography; MEG = magnetoencephalography; NAA = N-acetyl 
aspartate; mI = myoinositol; AD = Alzheimer’s disease; MCI = mild cognitive impairment; ROI = region 
of interest  
Table 3. Comparison of different brain imaging techniques for AD, with relative advantages 
and disadvantages, and usefulness for AD-MCI differentiation  
Structural MRI is nowadays a standard technique for this purpose, but cheaper techniques, 
such as CT, may still play a role, even more so in underdeveloped countries. Structural brain 
imaging, such as CT or MRI, is quite useful for the differential diagnosis of AD with non-
neurodegenerative diseases. PET and SPECT are not sufficiently accurate to replace clinical 
judgment, though they supplement the diagnosis of AD and MCI and help to improve the 
accuracy of diagnosis. Neuroimaging can be very useful for differentiating AD from 
frontotemporal dementia as well.  
At this moment the rest of the neuroimaging techniques previously mentioned are more used 
for research than for clinical purposes. Part of the problem is that the brain imaging 
sensitivities and relative utility of each one of them in AD and MCI are not clearly established. 
The bulk of neuroimaging research in AD continues to be centered on glucose metabolism, 
perfusion and tissue content. In the future it is likely the functional neuroimaging techniques 
will continue to expand. Their refinement will bring greater clarity in the diagnosis of AD as 
well in the MCI status. Combination of brain images approaches, some of them at least based 
on molecular issues, such as amyloid imaging, may be promising.  
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